As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer…

Antimicrobial resistance (AMR), or the resistance of pathogens to antibiotics, antivirals, antifungals and antiparasitics has been declared by the…

Antimicrobial pollution is a major global health and environmental risk. Shawview Consulting’s Brendan Shaw and Nicolai Schaaf of SIWI uncover what…

In conversation at the FT’s Global Pharmaceutical & Biotechnology Conference last month, Sandoz CEO Richard Saynor outlined the current status…

Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces…

Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and…

In a wide-ranging interview CEO Bertrand Ducrey introduces Debiopharm’s unique business focus on drug improvement, drug delivery, and drug…

On 25 November 2020, the European Commission adopted a Pharmaceutical Strategy for Europe with the stated aim of ensuring that “patients have access…

On 25 November, the European Commission adopted a new strategy meant to, among others, allow Europe to cover its pharmaceutical needs, including in…

Dr Pierre Meulien, executive director of the Innovative Medicines Initiative (IMI), the world’s largest life science public-private partnership…

June 9th 2020 saw the launch of a new action fund on antimicrobial resistance (AMR), with 23 leading biopharmaceutical companies committing to almost…

Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an…